2026年11月4日星期三
M
Wereldwijde Kroniek
Wereldwijd nieuws
Nintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei AsiaNintendo's Mario creator Miyamoto sees 'things we can do' even in AI era— 日经 Nikkei AsiaTaiwan airlines continue flights over Russia, rattling Europeans— 日经 Nikkei AsiaDebt costs curb growth for developing nations, Rockefeller official says— 日经 Nikkei AsiaChina's Temu, JD.com revamp business models amid tariff headwinds— 日经 Nikkei AsiaNidec's rise and fall fuels calls for sweeping overhaul of Japanese company— 日经 Nikkei AsiaAPEC host China to keep cars off street, close schools during Shenzhen summit— 日经 Nikkei AsiaJapan regional banks form united front on cybersecurity— 日经 Nikkei AsiaThe best is yet to come: Asia's chance to reimagine AI— 日经 Nikkei Asia

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

Bron Nature 医学研究6 dagen geleden
Samenvatting van de inhoud

Deze site biedt alleen een index van titels en samenvattingen. De volledige inhoud en het auteursrecht behoren toe aan de oorspronkelijke uitgever. Klik op de originele link om te lezen.

Ga naar het origineel
Behorend kanaal
Gezondheid
Behorende regio
Wereldwijd perspectief
Taal van het origineel
English
Itemnummer
health-a97f47b5

Comments 0 comments

No comments yet. Be the first.

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial · Wereldwijde Kroniek